Candel Therapeutics logo
Candel Therapeutics
CADL | NASDAQ
Chart Builder DCF Calculator
$5.81
-$0.39 (-6.29%)
At close: Nov 16, 2026, 4:00 PM ET
$5.76
-$0.05 (-0.86%)
After-hours: Nov 16, 2026, 7:55 PM ET

Candel Therapeutics Company Profile

Company profile explained

Company Profile

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

Key Executives

Name Position
Paul-Peter Tak FOCIS President, Chief Executive Officer & Director
Ileen Winick Chief People Officer
Charles Schoch Senior VP, CFO, Treasurer & Secretary
Francesca Barone Chief Scientific Officer
Mark Sims Chief Commercial Officer
Seshu Tyagarajan Chief Technical & Development Officer
Susan Stewart Chief Regulatory Officer
Theodore Jenkins Vice President of Investor Relations & Business Development
William Nichols Garrett Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 11, 2026 4 Filing
Sep 10, 2026 4 Filing
Sep 10, 2026 3 Filing
Sep 10, 2026 8-K Current Report
Sep 09, 2026 8-K Current Report
Aug 19, 2026 4 Filing
Aug 13, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Candel Therapeutics
Candel Therapeutics logo
Country United States
IPO Date Jul 27, 2021
Industry Biotechnology
Sector Healthcare
Employees 55
CEO Paul-Peter Tak

Contact Details

117 Kendrick Street Needham, Massachusetts 02494 United States

Stock Details

Ticker Symbol CADL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001841387
CUSIP Number 137404109
ISIN Number US1374041093
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.